ImmuPharma plc (LON:IMM – Get Free Report) traded up 12.5% on Thursday . The stock traded as high as GBX 5.80 ($0.07) and last traded at GBX 5.50 ($0.07). 19,527,068 shares were traded during mid-day trading, a decline of 23% from the average session volume of 25,520,734 shares. The stock had previously closed at GBX 4.89 ($0.06).
ImmuPharma Stock Down 3.7 %
The business has a 50 day moving average price of GBX 2.14 and a 200-day moving average price of GBX 1.85. The firm has a market cap of £21.65 million, a price-to-earnings ratio of -520.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- How Can Investors Benefit From After-Hours Trading
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
